Alpha 2.0
Login Register
» Authors » Paola Mencarini

Paola Mencarini

Explore the profile of Paola Mencarini including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 19
Citations 160
Followers 0
Related Specialties
Infectious Diseases
Public Health
Pharmacology
Top 10 Co-Authors
Fabrizio Palmieri
Gina Gualano
Silvia Mosti
Maria Musso
Enrico Girardi
Giuseppe Ippolito
Raffaella Libertone
Pietro Vittozzi
Emanuele Nicastri
Angela Cannas
Published In
Int J Infect Dis
Antibiotics (Basel)
Antimicrob Resist Infect Control
PLoS One
J Infect Public Health
Affiliations
Soon will be listed here.
Recent Articles
1.
Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital
Gualano G, Musso M, Mencarini P, Mosti S, Cerva C, Vittozzi P, et al.
Antibiotics (Basel) . 2025 Jan; 14(1. PMID: 39858293
: Tuberculosis (TB) is preventable and curable, but multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant challenges worldwide due to the limited treatment options, lengths of therapies, and...
2.
Clinical Utility of Induced Sputum and Bronchoalveolar Lavage Cultures in Diagnosing Nontuberculous Mycobacterial Pulmonary Disease
Licata M, Mencarini P, Mastrobattista A, Carli S, Cerva C, Mosti S, et al.
Pathogens . 2025 Jan; 13(12. PMID: 39770324
Diagnosing non-tuberculous mycobacterial pulmonary disease (NTM-PD) in patients unable to produce sputum spontaneously requires invasive procedures to obtain valid respiratory specimens. In this retrospective study, we evaluated the results of...
3.
Cognitive outcomes and psychological symptoms in an Italian cohort with post-acute COVID-19 condition (PACC)
Vergori A, Del Duca G, Borrelli P, Brita A, Pinnetti C, Mastrorosa I, et al.
Heliyon . 2024 Oct; 10(20):e39431. PMID: 39469684
Background: We aim to investigate the proportion of patients (pts) with long-term cognitive outcomes (CO) of PACC and identify associated features. Methods: We assessed participants through a neuropsychological assessment. The...
4.
Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study
Vergori A, Matusali G, Cimini E, Bordi L, Borrelli P, Lanini S, et al.
Vaccines (Basel) . 2024 Jul; 12(7). PMID: 39066422
. We aimed to report the real-world use and outcomes over time in immunocompromised individuals receiving tixagevimab/cilgavimab (T/C) pre-exposure prophylaxis (PrEP). . This observational study included participants who received T/C...
5.
Diagnosis of Tuberculosis in a Case of Chronic Urticaria following Omalizumab Therapy
Zolezzi A, Gualano G, Licata M, Mosti S, Mencarini P, Papagni R, et al.
Antibiotics (Basel) . 2023 Dec; 12(12). PMID: 38136689
In Italy, tuberculosis (TB) incidence in the last decade has remained constant at under 10 cases/100,000 inhabitants. In the Philippines, TB annual incidence is greater than 500 cases/100,000 inhabitants. Omalizumab...
6.
Utility of Liver Biopsy in the Diagnosis and Management of Possible Drug-Induced Liver Injury in Patients Receiving Antituberculosis Therapy: A Retrospective Study
Gualano G, Zace D, Mosti S, Mencarini P, Musso M, Libertone R, et al.
Infect Dis Rep . 2023 Dec; 15(6):735-746. PMID: 38131879
Background: Drug-induced liver injury (DILI) secondary to ATT treatment (TB-DILI) is reported in 2-28% of patients. We present here a series of clinical cases of suspected DILI arising during antituberculosis...
7.
Recovery from Triple Infection with SARS-CoV-2, RSV and Influenza virus: A case report
Guido G, Lalle E, Mosti S, Mencarini P, Lapa D, Libertone R, et al.
J Infect Public Health . 2023 May; 16(7):1045-1047. PMID: 37196367
The overall probability of infection with RSV, influenza virus, or SARS-CoV-2 in the general population is assessed as high by the ECDC. A high level of respiratory virus circulation increases...
8.
What is the impact of post-COVID-19 syndrome on health-related quality of life and associated factors: a cross-sectional analysis
Mastrorosa I, Del Duca G, Pinnetti C, Lorenzini P, Vergori A, Brita A, et al.
Health Qual Life Outcomes . 2023 Mar; 21(1):28. PMID: 36949439
Background: After the acute phase, symptoms or sequelae related to post-COVID-19 syndrome may persist for months. In a population of patients, previously hospitalized and not, followed up to 12 months...
9.
Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital
Lorenzini P, Di Gennaro F, Girardi E, Abbonizio M, Abdeddaim A, Agostini E, et al.
Int J Infect Dis . 2021 Mar; 105:532-539. PMID: 33676001
Background: Limited data are available about the predictors and outcomes associated with prolonged SARS-CoV-2 RNA shedding (VS). Methods: A retrospective study including COVID-19 patients admitted to an Italian hospital between...
10.
Dermatological manifestations during COVID-19 and histological picture: Description of two clinical cases
Mencarini P, Scarabello A, Del Nonno F, Lalle E, Falasca L, Gualano G, et al.
J Dermatol . 2021 Feb; 48(5):651-656. PMID: 33624293
It is not yet entirely clear what is the relevance of skin symptoms and what clinical implications are related to their appearance in COVID-19 patients. We describe two cases of...